{"organizations": [], "uuid": "2ebb99ede7f6695b6dc8b3fde8daa9640c582ad9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-hybrigenics-fy-operating-loss-wide/brief-hybrigenics-fy-operating-loss-widens-to-7-4-million-euros-presents-update-on-inecalcitol-clinical-studies-idUSFWN1S31Q4", "country": "US", "domain_rank": 408, "title": "Hybrigenics FY Operating Loss Widens To 7.4 Million Euros, Presents Update On Inecalcitol Clinical Studies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-27T03:21:00.000+03:00", "replies_count": 0, "uuid": "2ebb99ede7f6695b6dc8b3fde8daa9640c582ad9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-hybrigenics-fy-operating-loss-wide/brief-hybrigenics-fy-operating-loss-widens-to-7-4-million-euros-presents-update-on-inecalcitol-clinical-studies-idUSFWN1S31Q4", "ord_in_thread": 0, "title": "Hybrigenics FY Operating Loss Widens To 7.4 Million Euros, Presents Update On Inecalcitol Clinical Studies", "locations": [], "entities": {"persons": [{"name": "hybrigenics", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - HYBRIGENICS SA:\n* FY REVENUE EUR 0 MILLION VERSUS EUR 1.5 MILLION (RESTATED) YEAR AGO\n* FY OPERATING LOSS EUR 7.4 MILLION VERSUS LOSS OF EUR 4.0 MILLION (RESTATED) YEAR AGO\n* FY NET LOSS EUR 8.0 MILLION VERSUS LOSS OF EUR 5.3 MILLION (RESTATED) YEAR AGO\n* END-DEC CASH POSITION OF CONTINUED ACTIVITIES EUR 7.0 MILLION VERSUS EUR 8.5 MILLION (RESTATED) YEAR AGO\n* 87 PATIENTS RECRUITED IN INECALCITOL PHASE II ACUTE MYELOID LEUKEMIA STUDY\n* PHASE II CHRONIC MYELOID LEUKEMIA STUDY: INECALCITOL SHOWS ABILITY TO DECREASE RESIDUAL CML DISEASE\n* PHASE II CHRONIC MYELOID LEUKEMIA STUDY: INECALCITOL EFFECTS BEYOND USUAL EFFECTS OF IMATINIB\n* DECISION ON LAUNCH OF NEXT CLINICAL TRIAL OF INECALCITOL IN CML TO BE MADE AFTER AML STUDY RESULTS\n* PHASE II AML INECALCITOL STUDY: TO ENROL 110 PATIENTS BEFORE END-2018, FINAL RESULTS EXPECTED IN 2019 Source text: bit.ly/2HAcCss (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://bit.ly/2HAcCss", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T03:21:00.000+03:00", "crawled": "2018-04-27T17:06:56.023+03:00", "highlightTitle": ""}